Umbricht, Christoph A - Search Results

Search collections:

Sort by:	Display results:	Output format:

CERN Document Server	2 records found	Search took 0.56 seconds.

Alpha-PET for Prostate Cancer: Preclinical investigation using 149Tb-PSMA-617 / Umbricht, Christoph A. (PSI, Villigen) ; Gracheva, Nadezda (PSI, Villigen) ; Johnston, Karl (CERN) ; Schibli, Roger (PSI, Villigen ; Zurich, ETH) ; van der Meulen, Nicholas P. (PSI, Villigen) ; Müller, Cristina (PSI, Villigen ; ETH, Zurich) ; Bernhardt, Peter (Chalmers U. Tech.) ; Koster, Ulli (Laue-Langevin Inst.)
In this study, it was aimed to investigate$^{149}$Tb-PSMA-617 for targeted α-therapy (TAT) using a mouse model of prostate-specific membrane antigen (PSMA)-expressing prostate cancer.$^{149}$Tb-PSMA-617 was prepared with >98% radiochemical purity (6 MBq/nmol) for the treatment of mice with PSMA-positive PC-3 PIP tumors.$^{149}$Tb-PSMA-617 was applied at 1 × 6 MBq (Day 0) or 2 × 3 MBq (Day 0 & Day 1 or Day 0 & Day 3) and the mice were monitored over time until they had reached a pre-defined endpoint which required euthanasia. The tumor growth was significantly delayed in mice of the treated groups as compared to untreated controls (p < 0.05). [...]
2019 - Published in : Sci. Rep. 9 (2019) 17800 Fulltext: PDF;

Detailed record - Similar records

Preclinical investigations and first-in-human application of $^{152}$Tb-PSMA-617 for PET/CT imaging of prostate cancer / Müller, Cristina (PSI, Villigen) ; Singh, Aviral (Unlisted, DE ; Unlisted, NL) ; Umbricht, Christoph A (PSI, Villigen) ; Kulkarni, Harshad R (Unlisted, DE) ; Johnston, Karl (CERN) ; Benešová, Martina (PSI, Villigen) ; Senftleben, Stefan (Unlisted, DE) ; Müller, Dirk (Unlisted, DE) ; Vermeulen, Christiaan (PSI, Villigen) ; Schibli, Roger (ETH, Zurich (main) ; PSI, Villigen) et al.
The results of this study demonstrate the successful preparation and preclinical testing of $^{152}$Tb-PSMA-617 and its first application in a patient with mCRPC. This work could pave the way towards clinical application of other Tb radionuclides in the near future, most importantly $^{161}$Tb, which has promising decay characteristics for an effective treatment of mCRPC patients..
2019 - 10 p. - Published in : EJNMMI Res. 9 (2019) 68 fulltext from publisher: PDF;

Detailed record - Similar records

See also: similar author names
1	Umbricht, C A
1	Umbricht, Ch
1	Umbricht, Christoph A.

Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.

Haven't found what you were looking for? Try your search on other servers:
Umbricht, Christoph A in Amazon Umbricht, Christoph A in CERN EDMS Umbricht, Christoph A in CERN Intranet Umbricht, Christoph A in CiteSeer Umbricht, Christoph A in Google Books Umbricht, Christoph A in Google Scholar Umbricht, Christoph A in Google Web Umbricht, Christoph A in IEC	Umbricht, Christoph A in IHS Umbricht, Christoph A in INSPIRE Umbricht, Christoph A in ISO Umbricht, Christoph A in KISS Books/Journals Umbricht, Christoph A in KISS Preprints Umbricht, Christoph A in NEBIS Umbricht, Christoph A in SLAC Library Catalog Umbricht, Christoph A in Scirus

CERN Document Server

Access articles, reports and multimedia content in HEP

Main menu

CERN Accelerating science